OR WAIT null SECS
December 09, 2020
CDMO HALIX will manufacture the drug substance for AstraZeneca’s COVID-19 vaccine candidate, AZD1222, at commercial scale at its cGMP facility in the Netherlands.
December 08, 2020
The company will expand its micronization abilities for highly potent drug compounds through this investment.
December 07, 2020
The companies have entered into an agreement for next-generation, mesothelin-directed CAR-T cell therapies for the treatment of solid tumors.
December 03, 2020
The collaboration addresses the need for risk mitigation plans in cell therapies.
The gene therapy increases the ability of retina cells to make a soluble form of CD59, a protein that shields the retina from damage, to prevent additional damage and to preserve vision.
Under the terms of the partnership, Colorcon will work to accelerate i2O’s research and development efforts.
December 01, 2020
The expansion of the companies’ partnership will integrate lead optimization efforts to advance cancer immune therapy drug discovery.
Dolomite Microfluidics and MilliporeSigma have begun a collaboration to release off-the-shelf microfluidic device kits for the fabrication of PLGA particles.
Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters.
November 30, 2020
The companies have entered into a global collaboration and license agreement to develop zuranolone (SAGE-217) for major depressive disorder, postpartum depression (PPD), and SAGE-324 for essential tremor and other neurological disorders.